View PDF Version
 
DOI: 10.1039/A903141C (Paper) Reference Section for: J. Chem. Soc., Perkin Trans. 1, 1999, 2699-2711

Synthesis and serotonergic activity of a series of 2-(N-benzyl)carboxamido-5-substituted-N,N-dimethyltryptamine derivatives: novel antagonists for the vascular 5-HT1B-like receptors

(Note: The full text of this document is currently only available in the PDF Version )

Gerard P. Moloney, Graeme R. Martin, Neil Mathews, Heather Hobbs, Susan Dodsworth, Pang Yih Sang, Cameron Knight, Miles Maxwell and Robert C. Glen

Abstract

The synthesis and vascular 5-HT1B-like receptor activity of a novel series of 2-(N-benzyl)carboxamido-5-substituted-N,N-dimethyltryptamine derivatives is described. Modifications to the 5-ethylene linked heterocycle are explored. Compounds such as N-benzyl-5-[2-(phthalimido)ethyl]-3-[2-(dimethylamino)ethyl]-1H-indole-2-carboxamide 22 (pKB = 7.33), the 2-aminobenzyl analogue 24 (pKB = 7.19), which both contain a phthalimide group, and N-benzyl-5-[2-(1-benzyl-2,5-dioxoimidazolidin-4-yl)ethyl]-3-[2-(dimethylamino)ethyl]-1H-indole-2-carboxamide 81 (pKB = 7.05), which incorporates an N-benzylhydantoin moiety, have good 5-HT1B-like affinity and indicate that there may be a hydrophobic binding pocket within the vascular 5-HT1B-like receptor previously not considered. Compounds including N-benzyl-3-[2-(dimethylamino)ethyl]-5-[2-(2,4-dioxo-1,3-thiazolidinyl)ethyl]-1H-indole-2-carboxamide 39 (pKB = 7.35) and the dimethyl analogue 46 (pKB = 7.48) which contain a 2,4-thiazolidinedione moiety have good vascular 5-HT1B-like receptor affinity and show that the sulfur atom is well tolerated. Compound 61 which includes a methylsulfonyl substituent on the 1-nitrogen of the hydantoin ring system has the highest recorded 5-HT1B-like affinity for this series (pKB = 7.54) and it is proposed that this functional group can interact with a secondary hydrogen bonding region within the receptor. Compounds 22, 24, 39, 46, 61 and 81 also exhibited good selectivity over the α1-adrenoceptors. The most selective compound from this series is 46 which contains a 5,5-dimethylthiazolidine-2,4-dione group and which is 66-fold selective over the α1-adrenoceptors. This finding is consistent with the previous discovery that 5,5-dimethyl substitution on the hydantoin group in a related series of compounds afforded superior selectivity for 5-HT1B-like receptors over α1-adrenoceptors and other 5-HT receptors, in particular 5-HT2A receptors, relative to unsubstituted hydantoin analogues. The selectivity of these compounds for the vascular 5-HT1B-like receptor is discussed. Structure–activity relationship indicated a significant steric requirement of the 5-HT1B-like receptor subtype. Potential modes of binding for several of the compounds to a vascular 5-HT1B-like receptor pharmacophore model are also proposed.

References

  1. M. M. Rapport, A. A. Green and I. H. Page, Fed. Proc., 1947, 6, 184 Search PubMed.
  2. (a) C. Gluchowski, T. A. Branchek, R. L. Weinshank and P. R. Hartig, Annu. Rep. Med. Chem., 1993, 28, 29 Search PubMed; (b) P. R. Hartig, N. Adham, J. Zgombick, R. Weinshank and T. Branchek, Drug. Dev. Res., 1992, 26, 215 CAS.
  3. G. R. Martin and P. P. A. Humphrey, Neuropharmacology, 1994, 33, 261 CrossRef CAS.
  4. D. Hoyer, D. E. Clarke, J. R. Fozard, P. R. Hartig, G. R. Martin, E. J. Mylecharane, P. R. Saxena and P. Humphrey, Pharmacol. Rev., 1994, 46, 157 Search PubMed.
  5. E. Zifa and G. Fillion, Pharmacol. Rev., 1992, 44, 401 Search PubMed.
  6. D. Hoyer and G. R. Martin, Neuropharmacology, 1997, in press Search PubMed.
  7. P. M. Vanhoutte, P. P. A. Humphrey and M. Spedding, Pharmacol. Rev., 1996, 48, 1 Search PubMed.
  8. P. R. Hartig. Hartig, D. Hoyer, P. P. A. Humphrey and G. R. Martin, Trends. Pharmacol. Sci., 1996, 17, 103 CrossRef CAS.
  9. P. P. A. Humphrey, W. Feniuk, M. J. Perren, H. E. Connor, A. W. Oxford, I. H. Coates and D. Butina, Br. J. Pharmacol., 1988, 94, 1123 CAS.
  10. K. L. Dechant and S. P. Clissold, Drugs, 1992, 43, 776 Search PubMed.
  11. P. C. North, Migraine Therapy - Serotonin to Sumatriptan in Medicinal Chemistry: Principles and Practice, ed. F. G. King, The Royal Society of Chemistry, 1994 Search PubMed.
  12. R. C. Glen, A. P. Hill, G. R. Martin and A. D. Robertson, Headache, 1994, 34, 307 Search PubMed.
  13. R. C. Glen, G. R. Martin, A. P. Hill, R. M. Hyde, P. M. Woollard, J. A. Salmon, J. Buckingham and A. D. Robertson, J. Med. Chem., 1995, 38, 3566 CrossRef CAS.
  14. L. J. Street, R. Baker, J. L. Castro, M. S. Chambers, A. R. Guiblin, S. C. Hobbs, V. G. Matassa, A. J. Reeve, M. S. Beer, D. N. Middlemiss, A. J. Noble, J. A. Stanton, K. Scholey and R. J. Hargreaves, J. Med. Chem., 1993, 36, 1529 CrossRef CAS.
  15. P. Schoeter and D. Hoyer, Naunyn - Schmiedeberg's Arch. Pharmacol., 1989, 340, 135.
  16. S. J. Peroutka and B. G. McCarthy, Eur. J. Pharmacol., 1989, 163, 133 CrossRef CAS.
  17. E. Hamel, Current Drugs: Serotonin ID Research Alert, 1996, 1, 19 Search PubMed.
  18. G. R. Martin, Serotonin Receptor Involvement in the Pathogenesis and Treatment of Migraine, in: Blue Books on Neurology, eds S. Silberstein and P. J. Goadsby, Butterworth-Heinemann, 1997 Search PubMed.
  19. E. P. McFadden, J. G. Clarke, G. J. Davies, J. C. Kaski, A. W and M. A. Maseri, New Eng. J. Med., 1991, 324, 648 CAS.
  20. P. Golino, F. Piscione, J. T. Willerson, M. Cappelli-Bigazzi, A. Focaccio, B. Villari, C. Indolfi, E. Russolillo, M. Condorelli and M. Chiariello, New Eng. J. Med., 1991, 324, 641 CAS.
  21. A. Maseri, Circulation, 1990, I1-I3 Search PubMed.
  22. D. J. Fitzgerald, L. Roy, F. Catella and G. A. Fitzgerald, New Engl. J. Med., 1986, 315, 983 CAS.
  23. P. B. Bradley, G. Engel, W. Feniuk, J. R. Fozard, P. P. A. Humphrey, D. N. Middlemiss, E. J. Mylecharane, B. P. Richardson and P. R. Saxena, Neuropharmacology, 1986, 25, 563 CrossRef CAS.
  24. A. L. Scherbel and J. N. Harrison, Angiology, 1959, 10, 29 Search PubMed.
  25. (a) European Patent EP 0 533 266 A1, 1992; (b) Eurpoean Patent EP 0 533 267 A1, 1992; (c) European Patent EP 0 533 268 A1, 1992; (d) J. W. Clitherow, D. I. C. Scopes, M. Skingle, C. C. Jordan, W. Feniuk, I. B. Campbell, M. C. Carter, E. W. Collington, H. E. Connor, G. A. Higgins, D. Beattie, H. A. Kelly, W. L. Mitchell, A. W. Oxford, A. H. Wadsworth and M. B. Tyers, J. Med. Chem., 1994, 37, 2253 CrossRef CAS.
  26. M. Skingle, A. J. Sleight and S. Feniuk, Neuropharmacology, 1995, 34, 377 CrossRef CAS.
  27. D. M. Walsh, D. T. Beattie and H. E. Connor, Eur. J. Pharmacol., 1995, 287, 79 CrossRef CAS.
  28. G. P. Moloney, A. D. Robertson, G. R. Martin, S. MacLennan, N. Mathews, S. Dodsworth, Pang Yih Sang, C. Knight and R. C. Glen, J. Med. Chem., 1997, 40, 2347 CrossRef CAS.
  29. G. P. MoloneyG. R. MartinN. MathewsH. HobbsS. DodsworthPang Yih SangC. KnightM. WilliamsM. MaxwellR. C. ClenJ. Med. Chem., 1999, submitted Search PubMed.
  30. (a) O. Mitsunobu, Synthesis, 1981, 1 CrossRef CAS; (b) D. L. Hughes, Org. React., 1992, 42, 335 CAS.
  31. (a) I. Koppel, J. Koppel, F. Degerbeck, L. Grehn and U. Ragnarsson, J. Org. Chem., 1991, 56, 7172 CrossRef CAS; (b) J. R. Henry, L. R. Marcin, M. C. McIntosh, P. M. Scola, G. D. Harris, Jr and S. M. Weinreb, Tetrahedron Lett., 1989, 30, 5709 CrossRef CAS; (c) O. Mitsunobu, M. Wada and T. Sano, J. Am. Chem. Soc., 1972, 94, 679 CrossRef.
  32. R. R. Phillips, Org. React., 1959, 10, 143 CAS.
  33. F. R. Japp and P. Klingemann, in Methoden der organischen Chemie, (Houben-Weyl-Muller) Bd. X/3, S. 523, Thieme-Verlag, Stuttgart 1965 Search PubMed.
  34. B. Robinson, The Fischer Indole Synthesis, John Wiley and Sons: New York, 1982 Search PubMed.
  35. G. R. Martin and S. J. MacLennan, Naunyn - Schmiedeberg's. Arch. Pharmacol., 1990, 342, 111 CAS.
  36. S. J. MacLennan and G. R. Martin, Br. J. Pharmacol., 1992, 107, 418 CAS.
  37. Sybyl 6.1 molecular modelling package. Tripos Associates, St Louis MO 63144, U.S.A. 1992.
Click here to see how this site uses Cookies. View our privacy policy here.